Roivant Sciences Ltd. bought $336.9M of Immunovant (IMVT)
Executed Jan 13 2025, disclosed Jan 15 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Jan 15 2025), the stock returned -14.9% (delay-adjusted); from the execution session (Jan 13 2025), -15.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Roivant Sciences Ltd. (Director) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Immunovant, Inc. (IMVT). Across 1 priced purchase filing, the average 21-session return was +5.1% from execution and +5.1% from disclosure (delay-adjusted; derived). The largest single filing was $350.0M of IMVT (16,666,666 sh × $21.00, as filed), executed Dec 12 2025.
Healthcare · Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→16,666,666 sh × $21.00
Exec Dec 12 2025
Filed Dec 12 2025 · 5:17 PM ET